MA55801A - Formes solides d'un inhibiteur de glyt1 - Google Patents

Formes solides d'un inhibiteur de glyt1

Info

Publication number
MA55801A
MA55801A MA055801A MA55801A MA55801A MA 55801 A MA55801 A MA 55801A MA 055801 A MA055801 A MA 055801A MA 55801 A MA55801 A MA 55801A MA 55801 A MA55801 A MA 55801A
Authority
MA
Morocco
Prior art keywords
solid forms
glyt1 inhibitor
glyt1
inhibitor
solid
Prior art date
Application number
MA055801A
Other languages
English (en)
Inventor
Joe Ju Gao
Peter Sieger
Bing-Shiou Yang
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of MA55801A publication Critical patent/MA55801A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
MA055801A 2019-05-01 2020-04-30 Formes solides d'un inhibiteur de glyt1 MA55801A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201962841401P 2019-05-01 2019-05-01

Publications (1)

Publication Number Publication Date
MA55801A true MA55801A (fr) 2022-03-09

Family

ID=70740812

Family Applications (1)

Application Number Title Priority Date Filing Date
MA055801A MA55801A (fr) 2019-05-01 2020-04-30 Formes solides d'un inhibiteur de glyt1

Country Status (25)

Country Link
US (2) US11447474B2 (fr)
EP (1) EP3962911A1 (fr)
JP (2) JP7513349B2 (fr)
KR (1) KR20220004174A (fr)
CN (1) CN113784966B (fr)
AR (1) AR118839A1 (fr)
AU (1) AU2020266566B2 (fr)
BR (1) BR112021020883A2 (fr)
CA (1) CA3138288A1 (fr)
CL (2) CL2021002837A1 (fr)
CO (1) CO2021014260A2 (fr)
CR (1) CR20210545A (fr)
DO (1) DOP2021000224A (fr)
EA (1) EA202192925A1 (fr)
EC (1) ECSP21082195A (fr)
IL (1) IL287630A (fr)
JO (1) JOP20210295A1 (fr)
MA (1) MA55801A (fr)
MX (1) MX2021013341A (fr)
PE (1) PE20212263A1 (fr)
PH (1) PH12021552741A1 (fr)
SG (1) SG11202111972YA (fr)
TW (1) TW202106680A (fr)
UA (1) UA129159C2 (fr)
WO (1) WO2020223419A1 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7930336B2 (en) 2006-12-05 2011-04-19 Altera Corporation Large multiplier for programmable logic device
UA129159C2 (uk) * 2019-05-01 2025-01-29 Бьорінгер Інгельхайм Інтернаціональ Гмбх ТВЕРДІ ФОРМИ ІНГІБІТОРА GlyT1
KR20220125326A (ko) 2020-01-09 2022-09-14 디스크 메디슨, 인크. 적혈구형성 프로토포르피린증, x-연계된 프로토포르피린증, 또는 선천성 적혈구 조혈포르피린증을 글리신 운반 억제제로 치료하는 방법
BR112022026698A2 (pt) * 2020-08-13 2023-02-23 Boehringer Ingelheim Int Tratamento da deficiência cognitiva associada à esquizofrenia
CA3195702A1 (fr) * 2020-10-13 2022-04-21 Boehringer Ingelheim International Gmbh Procede de retraitement
WO2025140479A1 (fr) * 2023-12-29 2025-07-03 苏州科睿思制药有限公司 Forme cristalline d'iclépertine, son procédé de préparation et son utilisation

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL65843A (en) * 1977-08-11 1986-12-31 American Cyanamid Co Pharmaceutical compositions for the treatment of depression containing 3-aza-bicyclo(3.1.0)hexane derivatives and certain novel compounds of this type
CN101838271A (zh) * 2003-10-14 2010-09-22 辉瑞产品公司 作为甘氨酸转运蛋白抑制剂的二环[3.1.0]衍生物
CA2745690A1 (fr) * 2008-12-04 2010-06-10 Evgeny Zlotinikov Nouvelles formes polymorphes d'un derive d'azabicyclo-trifluoromethyl benzamide
WO2010078348A1 (fr) * 2008-12-29 2010-07-08 Vanderbilt University Inhibiteurs de glyt1 bicyclique et leurs procédés de production et d'utilisation
US9012489B2 (en) * 2011-08-03 2015-04-21 Boehringer Ingelheim International Gmbh Phenyl-3-aza-bicyclo[3.1.0]hex-3-yl-methanones and the use thereof as medicament
US10919891B2 (en) * 2017-04-27 2021-02-16 Takeda Pharmaceutical Company Limited Heterocyclic compound
UA129159C2 (uk) * 2019-05-01 2025-01-29 Бьорінгер Інгельхайм Інтернаціональ Гмбх ТВЕРДІ ФОРМИ ІНГІБІТОРА GlyT1
BR112022026698A2 (pt) * 2020-08-13 2023-02-23 Boehringer Ingelheim Int Tratamento da deficiência cognitiva associada à esquizofrenia
CA3195702A1 (fr) * 2020-10-13 2022-04-21 Boehringer Ingelheim International Gmbh Procede de retraitement

Also Published As

Publication number Publication date
PH12021552741A1 (en) 2022-07-11
JP7513349B2 (ja) 2024-07-09
CN113784966A (zh) 2021-12-10
JP2024100792A (ja) 2024-07-26
CO2021014260A2 (es) 2021-10-29
CN113784966B (zh) 2024-07-19
US11447474B2 (en) 2022-09-20
UA129159C2 (uk) 2025-01-29
ECSP21082195A (es) 2021-12-30
CA3138288A1 (fr) 2020-11-05
CL2024000829A1 (es) 2024-09-27
DOP2021000224A (fr) 2021-12-15
AU2020266566B2 (en) 2025-11-06
US20200347041A1 (en) 2020-11-05
NZ781254A (en) 2025-03-28
JP7714727B2 (ja) 2025-07-29
JOP20210295A1 (ar) 2023-01-30
KR20220004174A (ko) 2022-01-11
AU2020266566A1 (en) 2021-11-11
BR112021020883A2 (pt) 2022-04-19
PE20212263A1 (es) 2021-11-29
EA202192925A1 (ru) 2022-03-23
AR118839A1 (es) 2021-11-03
JP2022530630A (ja) 2022-06-30
WO2020223419A1 (fr) 2020-11-05
TW202106680A (zh) 2021-02-16
IL287630A (en) 2021-12-01
CR20210545A (es) 2021-12-23
SG11202111972YA (en) 2021-11-29
EP3962911A1 (fr) 2022-03-09
MX2021013341A (es) 2021-11-17
CL2021002837A1 (es) 2022-07-29
US20220332710A1 (en) 2022-10-20

Similar Documents

Publication Publication Date Title
MA55801A (fr) Formes solides d'un inhibiteur de glyt1
MA54526A (fr) NOUVELLES FORMES POLYMORPHES D'UN INHIBITEUR DE TGFBeta
EP3924352A4 (fr) Formes cristallines d'un inhibiteur rsk
EP3541807A4 (fr) Formes cristallines d'un inhibiteur de magl
IL282682A (en) Improved synthesis of key intermediate of kras g12c inhibitor compound
MA54458A (fr) Formes cristallines et formes salines d'un inhibiteur de kinase
EP3870178A4 (fr) Formes cristallines d'inhibiteurs de mnk
EP3893891A4 (fr) Formes solides d'un inhibiteur de cd73 et leur utilisation
MA52493A (fr) Sels d'un inhibiteur de fgfr
PT4058453T (pt) Síntese melhorada de composto inibidor de kras g12c
EP3947361A4 (fr) Sel et forme cristalline d'un inhibiteur de fak
MA53226A (fr) Sel et formes cristallines d'omecamtiv mecarbil
EP3841465A4 (fr) Structures de prédiction de branchement filtrées d'un processeur
EP3870181A4 (fr) Formes cristallines d'un inhibiteur d'alk2
EP3999517A4 (fr) Inhibiteurs de cd73
MA55614A (fr) Formes cristallines d'inhibiteur de pyridazinone trpc
EP3509594A4 (fr) Utilisations d'un inhibiteur d'homologue 2 de lysyl-oxydase
MA52004A (fr) Inhibiteurs d'o-glycoprotéine-2-acétamido-2-désoxy-3-d-glycopyranosidase
EP3807279A4 (fr) Sels pharmaceutiquement acceptables de sépiaptérine
EP3619208C0 (fr) Formes cristallines d'un composé inhibiteur de jak
EP3782987A4 (fr) Composé de benzo-pyrazole tenant lieu d'inhibiteur de la rho-kinase
EP3919491A4 (fr) Inhibiteur d'akt
MA56001A (fr) Formes de sel cristallin d'un inhibiteur de kinase
MA41827A (fr) Formes solvatées d'un inhibiteur de la tyrosine kinase de bruton
EP4337203A4 (fr) Inhibiteurs de l'interaction ménine-mll